Accumulated Other Comprehensive Income (Loss), Net of Tax in USD of China SXT Pharmaceuticals, Inc. from Q1 2018 to Q1 2025

Taxonomy & unit
us-gaap: USD
Description
Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.
Summary
China SXT Pharmaceuticals, Inc. quarterly Accumulated Other Comprehensive Income (Loss), Net of Tax history and change rate from Q1 2018 to Q1 2025.
  • China SXT Pharmaceuticals, Inc. Accumulated Other Comprehensive Income (Loss), Net of Tax for the quarter ending 31 Mar 2025 was $-1,075,522, a 4.85% decline year-over-year.
Source SEC data
View on sec.gov
Accumulated Other Comprehensive Income (Loss), Net of Tax, Quarterly (USD)
Accumulated Other Comprehensive Income (Loss), Net of Tax, YoY Quarterly Change (%)

China SXT Pharmaceuticals, Inc. Quarterly Accumulated Other Comprehensive Income (Loss), Net of Tax (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q1 2025 $-1,075,522 -$49,727 -4.85% 31 Mar 2025 20-F 31 Jul 2025 2025 FY
Q3 2024 $-568,853 +$449,958 +44.2% 30 Sep 2024 6-K 28 Mar 2025 2025 Q2
Q1 2024 $-1,025,795 -$828,224 -419% 31 Mar 2024 20-F 31 Jul 2025 2025 FY
Q3 2023 $-1,018,811 -$239,416 -30.7% 30 Sep 2023 6-K 05 Apr 2024 2024 Q2
Q1 2023 $-197,571 -$1,153,713 -121% 31 Mar 2023 20-F 13 Aug 2024 2024 FY
Q3 2022 $-779,395 -$1,538,215 -203% 30 Sep 2022 6-K 24 Feb 2023 2023 Q2
Q1 2022 $956,142 +$428,356 +81.2% 31 Mar 2022 20-F 31 Jul 2023 2023 FY
Q3 2021 $758,820 +$710,705 +1477% 30 Sep 2021 6-K 14 Jan 2022 2022 Q2
Q1 2021 $527,786 +$1,118,446 31 Mar 2021 20-F/A 19 May 2023 2022 FY
Q3 2020 $48,115 +$805,035 30 Sep 2020 6-K 28 Jan 2021 2021 Q2
Q1 2020 $-590,660 -$641,055 -1272% 31 Mar 2020 20-F 13 Aug 2021 2021 FY
Q3 2019 $-756,920 30 Sep 2019 6-K/A 22 May 2020 2020 Q2
Q1 2019 $50,395 -$206,978 -80.4% 31 Mar 2019 20-F 31 Jul 2020 2020 FY
Q1 2018 $257,373 31 Mar 2018 20-F 15 Aug 2019 2019 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.